Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans
AUPH•Corporate presentation outlines growth and pipeline plans
Aurinia highlighted continued commercial growth for lupus nephritis drug LUPKYNIS.
- Six months ended June 30, 2026: total revenue was $160.9 million, net income was $71.8 million, and operating cash flow was $85.1 million.
- 2026 guidance: total revenue of $315 million to $325 million; net product sales of $305 million to $315 million.
- Pipeline focus included advancing aritinercept development in autoimmune disease.
